Drug Sponsors

OSE Pharma, Effimune to merge

Friday, February 26, 2016

OSE Pharma, an immuno-oncology company with a specific immunotherapy activating T lymphocytes, currently in a registration phase III study, and Effimune, a biotech company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immune-oncology, have announce the signing of a proposed merger agreement.

[Read More]

AVROBIO launches in Cambridge, Massachusetts

Friday, February 19, 2016

AVROBIO, a clinical-stage biotechnology company developing transformative cell and gene therapies targeting cancer and rare diseases, has announced its launch plans. The company’s priority is to accelerate development of two novel cell and gene therapies pioneered within the labs of Dr. Christopher Paige and Dr. Jeffrey Medin (now at the Medical College of Wisconsin) at the University Health Network (UHN) in Toronto. Phase I programs will be in the clinic by early to mid-2016 in both acute myeloid leukemia (AML) and Fabry disease. The company will simultaneously work to expand its proprietary cell and gene therapy platform to treat additional indications.

[Read More]

Biogen joins Center for Therapeutic Target Validation

Wednesday, February 10, 2016

Biogen has joined the Center for Therapeutic Target Validation (CTTV), a public-private collaboration to improve the success rate for discovering new medicines. Originally formed by GlaxoSmithKline, the Wellcome Trust Sanger Institute and the European Bioinformatics Institute (EMBL-EBI), the CTTV fosters deep, ongoing interactions between academic and industry members for the purpose of developing open, transformative approaches to selecting and validating novel targets in drug development.

[Read More]

Abbott to Acquire Alere for 5.8B

Thursday, February 4, 2016

Abbott has announced a definitive agreement to acquire Alere, significantly advancing Abbott’s global diagnostics presence and leadership. Abbott will pay $56 per common share at a total expected equity value of $5.8 billion. Once the transaction is completed, Abbott will become a leading diagnostics provider of point-of-care testing. Abbott’s total diagnostics sales will exceed $7 billion after the close. 

[Read More]

Johnson & Johnson restructures, cuts 4% of medical devices business jobs

Wednesday, January 20, 2016

Johnson & Johnson has announced restructuring actions in its Medical Devices businesses to better serve the needs of customers and patients in today’s evolving healthcare marketplace. The company is undertaking actions to strengthen its go-to-market model, accelerate the pace of innovation, further prioritize key platforms and geographies, and streamline operations while maintaining high quality standards.

[Read More]